

POSTER PRESENTATION

Open Access

Proangiogenic neutrophilic-myeloid-derived suppressor cells emerge via two parallel pathways in renal cell carcinoma and melanoma

Jennifer Ko^{*}, Patricia Rayman, Dana Obery, Daniel Lindner, Ernest Borden, James Finke

From Society for Immunotherapy of Cancer 28th Annual Meeting
National Harbor, MD, USA. 8-10 November 2013

Targeted therapy including anti-angiogenic therapy, kinase inhibitors, and immunotherapy dominate cancer drug development in renal cell carcinoma (RCC) and malignant melanoma (MM), where traditional methodologies have failed. Myeloid-derived suppressor cells (MDSC) may represent a mode of resistance to such treatments and require investigation in human patients. Here we explore the relationship between conventional neutrophils and neutrophilic-MDSC (nMDSC) in RCC and MM. We show that T-cell suppressive nMDSC consist of hypodense CD11b⁺CD15⁺CD14⁻ immature CD16⁻ myelocytes/metamyelocytes and mature CD16⁺ neutrophils co-precipitating with peripheral blood mononuclear cells (PBMCs) in patient blood (n=22) and tumors (n=16). Such cells were not significantly present in healthy blood donors (n=5). In parallel, conventional neutrophils co-precipitating with red blood cells (RBCs) were found to be uniquely immunosuppressive when isolated from RCC or MM patients (n=8), but not when isolated from healthy blood donors (n=5)(p<0.05). Both hypodense n-MDSC as well as conventional neutrophils from cancer patients expressed increased levels of pro-angiogenic molecules (n=4) and enhanced tumor-associated angiogenesis of RCC and MM xenografts in nude mice (p<.0001). This functional shift in mature neutrophils was modeled in vitro upon exposure of healthy donor derived neutrophils to tumor cell conditioned medium; and, was associated with an increase in neutrophil production of immunosuppressive arginase and reactive oxygen species, as well as an increase in proangiogenic molecule expression and in vivo angiogenic activity (n=3, p<.0001). The data support a role for nMDSC that are both T-cell suppressive and pro-angiogenic in RCC

and MM cancer patients. Furthermore, our experiments suggest that n-MDSC arise via the parallel premature egress of bone marrow myeloid precursors as well as a functional switch in conventional neutrophil activity in cancer patients. Such activity is at least in part mediated via soluble tumor-derived factors which may circulate in patient blood. Ancillary strategies targeting myeloid cells may be an important part of future clinical trials to enhance the potency of targeted therapy.

Published: 7 November 2013

doi:10.1186/2051-1426-1-S1-P159

Cite this article as: Ko et al.: Proangiogenic neutrophilic-myeloid-derived suppressor cells emerge via two parallel pathways in renal cell carcinoma and melanoma. *Journal for ImmunoTherapy of Cancer* 2013 **1** (Suppl 1):P159.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit



Cleveland Clinic, Cleveland, OH, USA



© 2013 Ko et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.